User:Wikipedialuva/United Biomedical Asia
 | |
| Company type | Joint-stock company |
|---|---|
| Industry | Biotechnology |
| Founded | October 1998 |
| Headquarters | No. 45, Guangfu North Road, Hukou Township, Hsinchu County, Taiwan |
Key people | Chang Yi Wang (Chairman) |
| Website | www.ubiasia.com.tw |
United Biomedical, Asia Inc. is a Taiwanese company that focuses on the production of human and animal vaccines. It was founded in October 1998, with the support of the Development Fund of the Executive Yuan of the Republic of China and the Ministry of Economic Affairs.[1]
Vaccine Types
[edit]Animal vaccines
[edit]- Foot-and-mouth disease synthetic peptide vaccine: used for the prevention and treatment of foot-and-mouth disease using the UBITh platform, and is licensed for use in mainland China and Taiwan.[2][3]
- Pig immunocastration vaccine: used for pig immune castration.[3]
Human Vaccines
[edit]- UB-612 COVID-19 vaccine: a peptide vaccine candidate that was independently developed. United Biopharmaceuticals is responsible for the production of the upstream protein stock solution.[4][5][6]
Affiliated Enterprises
[edit]- UBI Pharma Inc.
- United BioPharma
- ShenLian Medical
- Vaxxinity (United Neuroscience, Inc. merged with COVAXX to form Vaxxinity on April 1, 2021)
References
[edit]- ^ "王長怡×王瑞瑜 突破台灣生技盲點｜天下雜誌". 天下雜誌 (in Chinese (Taiwan)). Retrieved 2019-10-06.
- ^ Kamel, Mohamed; El-Sayed, Amr; Castañeda Vazquez, Hugo (2019-06-01). "Foot-and-mouth disease vaccines: recent updates and future perspectives". Archives of Virology. 164 (6): 1501–1513. doi:10.1007/s00705-019-04216-x. ISSN 1432-8798.
- ^ a b Wang, Chang Yi; Walfield, Alan M. (2005-03-18). "Site-specific peptide vaccines for immunotherapy and immunization against chronic diseases, cancer, infectious diseases, and for veterinary applications". Vaccine. 23 (17–18): 2049–2056. doi:10.1016/j.vaccine.2005.01.007. ISSN 0264-410X. PMID 15755569.
- ^ "UBI Asia reapplies for COVID-19 vaccine EUA". Taipei Times. 2022-03-09. Retrieved 2023-03-20.
- ^ Wang CY, Hwang KP, Kuo HK, Peng WJ, Shen YH, Kuo BS, et al. (May 2022). "A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants". The Journal of Clinical Investigation. 132 (10). doi:10.1172/JCI157707. PMC 9106357. PMID 35316221.
- ^ "Taiwanese firm UBI-Asia inks COVID-19 vaccine deal with Paraguay". BioSpectrum Asia. 2021-06-22. Retrieved 2023-03-20.
Category:1998 establishments in Taiwan Category:Companies established in 1998 Category:Biotechnology companies of Taiwan Category:Vaccine producers